Supported by Opella
Chair:
Mr Paul Sinclair AM, President, International Pharmaceutical Federation, Australia
Introduction:
The symposium will focus on advancing pharmacists' knowledge of modern allergy management, particularly allergic rhinitis. It will introduce the innovative concept of "0% brain interference" in allergy treatment, highlighting the importance of non-sedating antihistamines in clinical practice. The introduction by Dr. Paul Sinclair will set the context for understanding how these advancements impact patient care in community pharmacy settings worldwide.
Programme:
| 13:00 – 13:03 | Welcome |
| Welcome to the Symposium from the Opella Global Head of Science Hub | |
| Dr Josephine Fubara, Opella, France | |
| 13:03 – 13:06 | Introduction |
| Present the objective of the symposium with the topics to cover and the respective speakers |
| Mr Paul Sinclair AM, President, International Pharmaceutical Federation, Australia | |
| 13:06 – 13:11 | Allergy Rhinitis overview |
| Brief introduction on Allergic Rhinitis condition and treatment options |
| Dr Ignacio J. Ansotegui, Head of Department of Allergy & Immunology Hospital Quironsalud Bizkaia, Executive Medical Director of the World Allergy Organization (WAO), Spain | |
| 13:11 – 13:24 | Conference 1: Antihistamines with 0% brain interference: the clinical evidence |
| Overview on the systematic review with a clinical perspective |
| Dr Ignacio Ansotegui, Hospital Quironsalud Bizkaia, Spain | |
| 13:24 – 13:34 | Conference 2: Management of antihistamines with no brain penetration in the community pharmacy |
| Review on Allergic Rhinitis and its management in the pharmacy settings, focusing on non-sedating antihistamines |
| Dr Ade Williams, Bedminster Pharmacy, UK | |
| 13:34 – 13:44 | Conference 3: Fexofenadine, a truly non-sedating antihistamine |
| Deep dive on fexofenadine properties and why it is a preferred choice |
| Dr Yorick Berger, France | |
| 13:44 – 13:47 | Interactive Quiz |
| Quiz to evaluate knowledge acquired by the audience |
| Mr Paul Sinclair AM, President, International Pharmaceutical Federation, Australia | |
| 13:47 – 13:57 | Q&A |
| Mr Paul Sinclair AM, President, International Pharmaceutical Federation, Australia | |
| 13:57 – 14:00 | Closure and remarks |
| Mr Paul Sinclair AM, President, International Pharmaceutical Federation, Australia | |
To educate pharmacists from different countries on the latest advancements in the allergy field
2. To raise awareness on non-sedating antihistamines, focusing on clinical evidence
3. To provide insights on community pharmacy management of allergic conditions
4. To present information on the efficacy and safety of fexofenadine in managing allergic conditions
5. To introduce the new concept of "0% brain interference" in allergic rhinitis treatment
6. To discuss truly non-sedating second generation antihistamines
Take home messages:
1. A summary of key messages from the symposium will be developed for wider distribution among pharmacists
2. Recorded videos in local languages will be made available to disseminate the information during local meetings
3. Speakers' presentations (slide decks) will be distributed to the attendees
4. Practical guidance on managing allergic rhinitis in community pharmacy settings
5. Understanding of the "0% brain interference" concept in allergy treatment
6. Knowledge of truly non-sedating second generation antihistamines and their benefits
